Healthcare Dec 02, 2021 09:44 AM (GMT+8) · EqualOcean
On December 1, Sanofi announced that it had reached an acquisition agreement with origin biotechnology GmbH, an Austrian private biotechnology company. The acquisition is expected to be completed in early December 2021. The price and specific terms of the transaction have not been disclosed. Origimm is a biotechnology R & D company dedicated to discovering toxic skin microbial components and antigens from bacteria causing skin diseases, such as acne. This transaction will integrate ori-001 into Sanofi's early R & D pipeline. Ori-001 is a recombinant protein based therapeutic acne vulgaris candidate vaccine, which entered the preliminary clinical study in the third quarter of 2021. Through this acquisition, Sanofi will continue to implement its global play to win strategy, seek growth opportunities and establish an industry-leading vaccine pipeline.